<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02665312</url>
  </required_header>
  <id_info>
    <org_study_id>CheckPoint</org_study_id>
    <nct_id>NCT02665312</nct_id>
  </id_info>
  <brief_title>Cardiotoxicity and Risk Factors in Patients With Colorectal Cancer Receiving Fluoropyrimidine</brief_title>
  <official_title>CHEmotherapy-induced Cardiotoxicity and Study of risK Factor Correlation in Patients With Colorectal Cancer Receiving Oral or INfusional Fluoropyrimidine Treatment - CHECKPOINT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione del Piemonte per l'Oncologia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione del Piemonte per l'Oncologia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      observational prospective study, designed for patients with colorectal cancer receiving for
      the first time 5-FU or capecitabine, with or without other chemotherapy combinations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients enrolled will be evaluated for cardiovascular risk factors and, if resulted at
      cardiovascular risk, they will be submitted to cardiac examination and therapy optimization
      before starting chemotherapy.

      Patients will be evaluated with 12-lead ECG and blood sample for TnI and NT pro-BNP before
      start chemotherapy and on day 3 of chemotherapy during the first, second and third cycle.

      All patients developing cardiovascular events will be submitted to blood sample for TnI,
      NT-proBNP, hsTnI and cardiac examination.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of the incidence of cardiovascular events during the first three cycles of therapy with capecitabine or 5-FU</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Colorectal Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with colorectal cancer receiving Oral or INfusional fluoropyrimidine Treatment
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed written informed consent

          -  Age ≥ 18 years

          -  Histologically confirmed adenocarcinoma of colon or rectum (any T, any N, any M)
             receiving for the first time 5-FU or capecitabine, with or without other chemotherapy
             combinations

        Exclusion Criteria:

          -  Prior treatment with fluoropyrimidines

          -  Prior or concurrent chest radiotherapy

          -  Any prior or concurrent treatment with cardiotoxic drug

          -  Any serious or uncontrolled cardiovascular disease (defined by the specialist during
             cardiac examination, see section 6.3.2 for details )
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Leone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IRCCS Candiolo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Celeste Cagnazzo, PhD</last_name>
    <phone>00390119933851</phone>
    <email>celeste.cagnazzo@ircc.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Lazzaro - ASL CN 2 Alba Bra</name>
      <address>
        <city>Alba</city>
        <state>Cuneo</state>
        <zip>12051</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Franchini, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione del Piemonte per l' Oncologia - IRCCS Candiolo</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Celeste Cagnazzo, PhD</last_name>
      <phone>00390119933851</phone>
      <email>celeste.cagnazzo@ircc.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Leone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandro Bonzano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilaria Depetris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Aglietta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Ordine Mauriziano di Torino</name>
      <address>
        <city>Turin</city>
        <zip>101028</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elisa Sperti, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Molinette - Oncologia Medica 1</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrizia Racca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Molinette - Oncologia Medica 2</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mario Airoldi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Cottolengo</name>
      <address>
        <city>Turin</city>
        <zip>10152</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alex Luca Gerbino, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Humanitas Gradenigo</name>
      <address>
        <city>Turin</city>
        <zip>10153</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Comandone, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale San Giovanni Bosco - ASL TO2</name>
      <address>
        <city>Turin</city>
        <zip>10154</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristiano Oliva, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2016</study_first_submitted>
  <study_first_submitted_qc>January 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2016</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cardiotoxicity</keyword>
  <keyword>fluoropyrimidine</keyword>
  <keyword>colorectal cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

